• Limpens J, van Werden W, Schroder F et al. Prostate carcinogenesis in N-methyl-N-nitrosurea (NMU)-testosterone-treated rats
• fed tomato powder Lycopene or energy-restricted diets. J Natl Canc Inst 96(7):554 Apr 2004
• Lippman S et al. Vitamin A derivatives in the prevention and treatment of human cáncer. J Am Coll Nutr 7:269-284, 1988
• Lippman S, et al. Cáncer Chemoprevention: Progress and promise. J Nat Cáncer Institute 90:1514-1528, 1998
• Liu S, I-Min L, Linsona P et al. A prospective study of physical activity and risk of prostate cáncer in US physicians. International
• Journal of Epidemiology 29:29-35, 2000
• Liu Y, Kyle E, Patel S, et al. Prostate cáncer chemoprevention agents exhibit selective activity against early stage prostate cáncer
• cells. Prostate Cáncer and Prostatic diseases 4,81-91, 2001
• Liu X, Kirschenbaum A, Yao S et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cáncer in
• vivo. J Urol 164(3 pt 1):820-825, 2000
• Loeb S, Roehl K, Antenor J et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group
• as predictor of prostate cáncer risk in men younger than 60 years old. Urology 2006;67:316-320
• Lonn E, Bosch J, Yusuf S. Effects of long-Term vitamin E supplementation on cardiovascular events and cáncer: A randomized
• controlled Trial. JAMA 293:1338-1347, 2005.
• Loomis D, Wing S. Is molecular epidemiology a germ theory for the end of the twentieth century? Int. J. Epidemiol. 19:1-3, 1990 Lopatkin N, Sivkov A, Walther C et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary
• tract symptoms a placebo-controlled, double-blind, multicenter trial. World J Urol. 23(2):139-146 Jun 2005.
• Lose G, Lalos O, Freedman R et al. Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a
• double-blind placebo controlled study in women. Am J Obstet Gynecol 189:1106-1113, 2003
• Lowe J, Frazee L. Update on prostate cáncer chemoprevention. Pharmacotherapy. 26(3):353-359, Mar 2006
• Lowe F, Fleshner N. Complementary Medication and Nutritional Supplementation Usage in Urology. Instructional Course . H0210
• IC. 97th Annual Meeting American Urological Association Orlando 2002
• Lowe F, Dreikhorn K, Borkowski A, et al. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for the
• treatment of BPH. The Prostate 37:187-193,1998
• Lowe J, Frazee L. Update on prostate cáncer chemoprevention. Pharmacotherapy. 26(3):353-359, March 2006
• Lowe F, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasía an update. Urology 53:671-678,1999
• Lowe F, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasía. Curr Opin Urol 8:27, 1998
• Lowe F. Evidence based results from complementary and alternative medicine in Urology. AUA News April/May 11(3):3-4, 2006
• Lu Q, Hung J, Heber D, et al. Inverse associations between plasma lycopene and other carotenoids and prostate cáncer. Cáncer
• Epidemiol Biomarkers Prev. 10(7):749-756, Jul 2001
• Lucia M, Torkko K Inflammation as a Target for Prostate Cáncer Chemoprevention:: Pathological and Laboratory Rationale. The
• Journal of Urology 171(2, Part 2 of 2): S30-S35 February 2004
• Machha A, Achike F, Mustafa A et al. Quercetin, a flavonoid antioxidant, modulates endothelium-derived nitric oxide bioavailability
• in diabetic rat aortas. Nitric Oxide. Apr 20, 2007
• McConnell J et al, for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute
• urinary retention and the need for surgical treatment among men with benign prostatic hyperplasía. N Engl J Med. 338:557–563, 1998 McNeal J, Bostwick D.Intraductal dysplasía: a premalig. lesion of the prostate. Hum Pathol 17: 64-71,1986 McNeal J. The prostate gland: morphology and pathobiology. Monographs in Urology 9:3, 1988
• McNeal J. Regional morphology and pathology of the prostate. Am J Clin Pathol 49:347-357,1968.
• MacDonald R et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasía BJU Int 85:836-841,1999
• MacDonald R, Ishani A, Rutks I et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasía. BJU Int. 85(7):836-841, May 2000
• Madersbacher H, Stohrer M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 75:452-456, 1995
• Magee P, Rowland I. Phyto-oestrogens their mechanism of action: current evidence for a role in breast and prostate cáncer. Br J Nutr 91(4): 513-531, 2004
• Maksem J, Johenning P et al. Prostatitis and aspiration biopsy cytology of prostate. Urology 32:263-268, 1988
• Malik A, Afaq S, Sarfaraz S, et al. Pomegranate fruit juice chemoprevention and chemotherapy of prostate cáncer. Proc Natl Acad Sci USA 102: 14813-14818,2005
• Maramag C, Menon M, Balaji K et al. Effect of vitamin C on prostate cáncer cells in vitro: effect on cell number, viability, and DNA synthesis. Prostate. 32(3):188-195, 1 Aug 1997
• Marks L, Hess D, Dorey F, et al. Tissue effects of saw palmetto and Finasteride: Use of biopsy cores for in situ Quantification of prostatic androgens Urology 57:999-1005, 2001
• Marks L, DiPaola R et al. PC-SPES: Herbal formulation for prostate cáncer. Urology 60(3):369-375, Sep 2002
• Marks L, Partin A, Epstein J et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasía. J Urol 163:1451-1456, 2000
• Marks L et al. Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasía. Urology 53:457-461,1999.
• Marks L, Partin A et al. Long-term Effects of Finasteride on Prostate Tissue Composition. Urology. 53(3):574-580, March 1999
• Máskarinec G, Morimoto Y, Hebshi S et al. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men. Eur J Clin Nutr. 60(12):1423-1429, Dec 2006
• Mattiasson A, Abrams P, van Kerrebroeck P et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 89:855-862,2002
• Matsumoto A ,Clark R, Huffman C, Swerdoff R. Potent DHT suppression by the novel dual 5alpha -reductase inhibitor dutasteride does not effect bone density, bone metabolism or lipid profiles in healthy men. European Urology Supplements, 2(1): 160-161, February 2003
• Mavropoulos J . Is there a role a low-carbohydrate ketogenic diet in the management of prostate cáncer?Urol 68(1):15-8 Jul 2006
• Maygarden S, Strom S, Ware JL. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasía and benign hyperplasía. Arch Pathol Lab Med. 116(3): 269-73 Mar 1992.
• Meares E Jr, Stamey T. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 5:492 ,1968
• Medscape Medical News. Omega-3 Fatty Acids May Lower Genetic Risk for Prostate Cáncer. http://www. medscape. com/ view article/ 558671. 21 Junio, 2007
• Mehta N. Cellular effects of hypercholesterolemia in modulation of cáncer growth and metastasís: a review of the evidence. Surg Oncol 6(3):179-185,1997
• Menchini-Fabris G, Giorgi P, Andreini F et al. New perspectives on the use of Pygeum Africanum in prostato-bladder pathology. Arch Ital Urol Nefrol Androl. 60:313–322, 1988
• Menter D et al. Selenium effects on prostate cell growth. Cáncer Epidemiology Biomarkers Prev 9(11):1171-1182, Nov 2000
• Messina M. Soy intake and cáncer risk: a review of the in vitro and in vivo data. Nutr Cáncer 21(2):113-131,1994
• Mettlin C, Selenskas S, Natarajan N. Beta-carotene and animal fats and their relationship to prostate cáncer risk: a case-control study. Cáncer 64(3): 605-612, 1989
• Meyer J, Gillatt D. PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cáncer. Prostate Cáncer Prostatic Dis. 5(1):13-15, 2002
• Mikhak B, Hunter D, Spiegelman D et al. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cáncer risk. Prostate 67(9):911-923, 15 Jun 2007
• Miller E et al. Tomato products, lycopene and prostate cáncer risk. Urol Clin Noth America (1):83-93, 29 Feb 2002
• Mills P, Beeson W, Phillips R. Cohort study of diet, lifestyle, and prostate cáncer in Adventist men. Cáncer 64(3):598-604, 1989.
• Milson I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760-766, 2001
• Mitropoulos D, Kyroudi A, Zervas A et al. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon®) on mást cell accumulation and glandular epithelium trophism in the rat prostate. World J Urol. 19(6):457-461, April 2002
• Mohan R, Challa A, Gupta S, Bostwick D, et al. Overexpression of ornithine decarboxylase in prostate cáncer and prostatic fluid in humans. Clin Cáncer Res. 5(1):143-147, Jan 1999
• Mohr B, Feldman H, Kalish L, Longcope C, McKinlay J. Are serum hormones associated with the risk of prostate cáncer? Prospec-tive results from the Mássachusetts Male Aging Study. Urology 57(5):930–935, 2001
• Montanari M. Montanari C Pilo-Veloso D; Beezer A; Mitchell J. Quim. Nova 21, 470, 1998
• Montanari E et al. Phytotherapy of benign prostatic hypertrophy without complications. Der informierte Arzt 6A:593-598, 1991
• Montironi R et al. Aneuploidy and nuclear features of prostatic intraepithelial neoplasía (PIN). J Cell Bioch Suppl 16: 47-53, 1992.
• Montironi R, Magi-Galluzzi C, Muzzonigro G, et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasía, and prostatic adenocarcinoma. J Clin Pathol 47(10): 906-913 Oct 1994